Medindia

X

Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso

Tuesday, December 30, 2008 General News J E 4
Advertisement
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania,December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG),the leading developer of microRNA-based molecular diagnostics, announcedtoday the introduction of its third diagnostic test, miRview(TM) meso. Thetest is now commercially available through Rosetta Genomics CLIA-certifiedlab in Philadelphia.

To order the test, physicians may contact 1-888-522-7971, or visit thecompany's website http://www.rosettagenomics.com.

"I am very excited to finally see a molecularly-based test that canobjectively differentiate mesothelioma from several types of carcinomas inthe lung with such high level of accuracy" noted Harvey Pass, MD, DivisionChief for Thoracic Surgery and Thoracic Oncology at the New York UniversityLangone Medical Center. "Ruling out Mesothelioma from lung cancer forindividuals that were exposed to asbestos can be difficult and challenging. Iam sure that this test will become an important tool for both oncologists andpathologists in obtaining the right diagnosis in these patients."

Malignant pleural mesothelioma is directly linked to exposure to asbestosparticles, as well as to various heavy metals. Rescue workers, shipyardworkers, and miners are at increased risk of developing mesothelioma.Currently, there is no single diagnostic test that is entirely conclusive forthis differentiation. In addition, pathological diagnosis may suffer fromsignificant inter-observer variability, and in the absence of a singlespecific and reliable test, mesothelioma can be difficult to identify fromother cancers.

miRview(TM) meso differentiates mesothelioma, a cancer connected toasbestos exposure, from other carcinomas in the lung. Currently, there is nosingle diagnostic test that is entirely conclusive for this differentiation.Each year, approximately 130,000 patients in the United States are diagnosedwith adenocarcinoma of the lung. miRview(TM) meso is available for $3170.

Rosetta Genomics currently has approximately $16M in cash, and it expectsto perform approximately 2,000 tests during 2009 in its laboratory inPhiladelphia, PA.

The company is now offering the following ground-breaking tests throughits clinical lab in Philadelphia:

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring, smallRNAs that act as master regulators and have the potential to form the basisfor a new class of diagnostics and therapeutics. Since many diseases arecaused by the abnormal activity of proteins, the ability to selectivelyregulate protein activity through microRNAs could provide the means to treata wide range of human diseases. In addition, microRNAs have been shown tohave different expression in various pathological conditions. As a result,these differences may provide for a novel diagnostic strategy for manydiseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leading developer of microRNA-basedmolecular diagnostics. Founded in 2000, the company's integrative researchplatform combining bioinformatics and state-of-the-art laboratory processeshas led to the discovery of hundreds of biologically validated novel humanmicroRNAs. Building on its strong IP position and proprietary platformtechnologies, Rosetta Genomics is working on the application of thesetechnologies in the development of a full range of microRNA-based diagnostictools. The company have their first three microRNA-based tests, miRview(TM)squamous, miRview(TM) mets, and miRview(TM) meso, commercially availablethrough its Philadelphia-based CLIA-certified lab.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's futureexpectations, plans and prospects, including without limitation, statementsrelating to the role of microRNAs in human physiology and disease, thepotential of microRNAs in the diagnosis and treatment of disease and thetiming of introduction of additional microRNA-based diagnostic tests,including miRview meso, miRview squamos and miRview mets, constituteforward-looking statements for the purposes of the safe harbor provisionsunder The Private Securities Litigation Reform Act of 1995. Actual resultsmay differ materially from those indicated by these forward-lookingstatements as a result of various important factors, including risks relatedto: Rosetta's approach to discover and develop novel diagnostics andtherapeutic tools, which is unproven and may never lead to commerciallyaccepted products or services; Rosetta's ability to fund and the results offurther pre-clinical and clinical trials; Rosetta's ability to obtain,maintain and protect the intellectual property utilized by Rosetta'sproducts; Rosetta's ability to enforce its patents against infringers and todefend its patent portfolio against challenges from third parties; Rosetta'sability to obtain additional funding to support its business activities;Rosetta's dependence on third parties for development, manufacture,marketing, sales, and distribution of products; Rosetta's ability tosuccessfully develop and commercialize its candidate tools, products andservices; Rosetta's ability to obtain regulatory clearances or approvals thatmay be required for its products and services; the ability to obtain coverageand adequate payment from health insurers for the products and servicescomprising Rosetta's technology; competition from others using technologysimilar to Rosetta's and others developing products for similar uses;Rosetta's dependence on collaborators; and Rosetta's short operating history;as well as those risks more fully discussed in the "Risk Factors" section ofRosetta's Annual Report on Form 20-F for the year ended December 31, 2007 asfiled with the Securities and Exchange Commission. In addition, anyforward-looking statements represent Rosetta's views only as of the date ofthis release and should not be relied upon as representing its views as ofany subsequent date. Rosetta does not assume any obligation to update anyforward-looking statements unless required by law.

Contact: Media & Investors, Ron Kamienchick, T: +1-(646)-509-1893, E:investors@rosettagenomics.com- miRview(TM) mets - This test can accurately identify the primary tumor site in patients presenting with metastatic cancer, as well in patients with Cancer of Unknown Primary (CUP). In the U.S., hundreds of thousands of patients are diagnosed each year with metastatic cancer, and approximately 70,000 patients are labeled CUP patients. miRview(TM) mets is available for $3650. - miRview(TM) squamous - This test differentiates between two subtypes of non small cell lung cancer (NSCLC). This diagnosis is important as some NSCLC patients have demonstrated varying response patterns ranging from a high incidence of severe or fatal internal bleeding in the lungs to overall poor response to treatment. In the US alone, approximately 170,000 patients are diagnosed each year with NSCLC. miRview(TM) squamous is available for $3170. - miRview(TM) meso - This test differentiates mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung. Currently, there is no single diagnostic test that is entirely conclusive for this differentiation. Each year, approximately 130,000 patients in the United States are diagnosed with adenocarcinoma of the lung. miRview(TM) meso is available for $3170.

SOURCE Rosetta Genomics Ltd
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Fisher Vista, LLC Reports Seventh Consecutive Year...
S
Accuray Incorporated to Present at 11th Annual Nee...